March 9, 2020 / 8:23 PM / a month ago

BRIEF-Xenon Pharmaceuticals Expects FDA Feedback On Phase 3 Protocol For XEN496 Early Within Q2

March 9 (Reuters) - Xenon Pharmaceuticals Inc:

* XENON PHARMACEUTICALS REPORTS 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* XENON PHARMACEUTICALS - ANTICIPATE TOP-LINE DATA FROM ONGOING XEN1101 PHASE 2B CLINICAL TRIAL IN ADULT FOCAL EPILEPSY LATER THIS YEAR

* XENON PHARMACEUTICALS INC - EXPECT FDA FEEDBACK ON PHASE 3 PROTOCOL FOR XEN496 EARLY WITHIN Q2 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below